AMRX vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELAN
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
Amneal Pharmaceuticals vs.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
Amneal Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Qiagen has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Qiagen had 7 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Qiagen and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.13 beat Qiagen's score of -0.37 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.
31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Qiagen received 233 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.12% of users gave Amneal Pharmaceuticals an outperform vote while only 60.29% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 4.23% compared to Amneal Pharmaceuticals' net margin of -6.88%. Qiagen's return on equity of 13.92% beat Amneal Pharmaceuticals' return on equity.
Amneal Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 27.71%. Qiagen has a consensus price target of $47.71, suggesting a potential upside of 20.73%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Amneal Pharmaceuticals is more favorable than Qiagen.
Summary
Qiagen beats Amneal Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMRX) was last updated on 2/21/2025 by MarketBeat.com Staff
